Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
RESEARCH TOOLSreports
XFOR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.26 - $1.60
Previous CloseN/A
Volume769.31K
Average Volume (3M)5.59M
Market Cap
$85.02M
Enterprise Value$77.67M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Mar 13, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding170,546,460
10 Day Avg. Volume2,123,704
30 Day Avg. Volume5,586,767
Standard Deviation0.27
R-Squared0.00056
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)75.91
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-38.91
Enterprise Value/Ebitda-0.58
Forecast
1Y Price Target
$2.17Price Target Upside361.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
X4 Pharmaceuticals News
PremiumCompany Announcements
X4 Pharmaceuticals Announces Strategic Restructuring Plans---
Bulls Say, Bears Say
Bulls Say
Financial StabilityNon-dilutive payments from the collaboration strengthen the balance sheet, potentially improving the company's cash runway into late-FY25.
Partnership And LicensingX4 Pharmaceuticals has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of mavorixafor in Europe, Australia, and New Zealand.
Strategic RestructuringThe strategic restructuring, including a reduction in headcount and annual spending, is seen as a prudent measure for long-term growth.
Bears Say
Capital NeedsDespite the collaboration, additional capital is still considered necessary to provide sufficient runway to topline data from the P3 4WARD trial.
Commercial ChallengesThe longer-than-expected time to diagnose and initiate therapy for new WHIM patients and the high commercial cost to onboard a patient are challenges faced by the company.
Market AdoptionMarket adoption of the drug has not been as robust as expected.
---
Ownership Overview
14.82% Insiders
7.55% Mutual Funds
31.82% Other Institutional Investors
36.99% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XFOR FAQ
What was X4 Pharmaceuticals Inc’s price range in the past 12 months?
X4 Pharmaceuticals Inc lowest stock price was $0.26 and its highest was $1.60 in the past 12 months.
What is X4 Pharmaceuticals Inc’s market cap?
X4 Pharmaceuticals Inc’s market cap is $85.02M.
When is X4 Pharmaceuticals Inc’s upcoming earnings report date?
X4 Pharmaceuticals Inc’s upcoming earnings report date is Mar 13, 2025 which is in 20 days.
How were X4 Pharmaceuticals Inc’s earnings last quarter?
X4 Pharmaceuticals Inc released its earnings results on Nov 13, 2024. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.171 by -$0.009.
Is X4 Pharmaceuticals Inc overvalued?
According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued.
Does X4 Pharmaceuticals Inc pay dividends?
X4 Pharmaceuticals Inc does not currently pay dividends.
What is X4 Pharmaceuticals Inc’s EPS estimate?
X4 Pharmaceuticals Inc’s EPS estimate is -0.17.
How many shares outstanding does X4 Pharmaceuticals Inc have?
X4 Pharmaceuticals Inc has 170,546,460 shares outstanding.
What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?
X4 Pharmaceuticals Inc reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.171. Following the earnings report the stock price went down -52.542%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in XFOR
---
X4 Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.17 (361.70% Upside)
$2.17 (361.70% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.1%
Last 30 Days ▲ 20.6%
Last 30 Days ▲ 20.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.08%
12-Months-Change
Fundamentals
Return on Equity
-26.35%
Trailing 12-Months
Asset Growth
2.81%
Trailing 12-Months
Company Description
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.
---
XFOR Company Deck
---
XFOR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted positive clinical trial results and strategic advancements for X4 Pharmaceuticals, particularly with mavorixafor's potential in chronic neutropenia and the successful launch of XOLREMDI. However, some concerns were noted regarding flat sales and early study discontinuations.Read More>---
XFOR Stock 12 Month Forecast
Average Price Target
$2.17
▲(361.70% Upside)
Technical Analysis
Alnylam Pharma
―
Vertex Pharmaceuticals
―
Agios Pharma
―
Karyopharm Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering XFOR
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
-6.82%
reiterated a buy rating 15 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -6.82% per trade.
---